Genentech, a member of the Roche Group, announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH)… read more.
Marsha Showman and Reena Patel (Leeds Health and Care Partnership) presented a poster describing how utilisation of health services was improved when people with long term conditions, including… read more.
Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events: 15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD Modeling of… read more.
In his keynote lecture Richard Cattell, Deputy Chief Pharmaceutical Officer, asked pharmacists to do three things: Make their voices heard in the development of the NHS 10-year plan… read more.
Eli Lilly and Company announced that data from the Phase III trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first… read more.
Madrigal Pharmaceuticals, Inc. a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), announced multiple resmetirom data presentations at the upcoming American Association… read more.
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA)… read more.
Rehab Elhiny (University College, Cork, Ireland and Minia University, Egypt) was awarded the best poster prize for her poster entitled ‘Goal attainment, medication adherence and guideline adherence in… read more.
Therapeutic advances in lung cancer Molecular testing before the start of treatment is good clinical practice (GCP) and confers considerable benefits in survival, according to Professor Joanna Chorostowska-Wynimko… read more.
Bristol Myers Squibb announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating obenfy (xanomeline and trospium chloride) in schizophrenia in… read more.
Plus Therapeutics a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.
Johnson & Johnson announced that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
